Processing...
Clinical Trials for Sarcoma
Search
Search
There are 145 active trials for advanced/metastatic sarcoma.
Click on a trial to see more information.
145 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with refractory locally advanced/metastatic TP53 (p53) wild-type solid tumors (Phase 1 also allows relapsed/refractory non-Hodgkin lymphoma) receive SA53-OS, an oral small-molecule MDM2 inhibitor designed to reactivate wild-type p53. Phase 2a expands to dedifferentiated liposarcoma with MDM2 amplification and other TP53 wild-type solid tumors, with SA53-OS given 3 days every 3 weeks at the RP2D.
ClinicalTrials.gov ID: NCT06578624
TrialFetch AI summary: Children and adults (1–50 years) with very high-risk solid tumors (e.g., refractory neuroblastoma, stage 4 rhabdomyosarcoma, metastatic Ewing sarcoma, osteosarcoma with unresectable/extrapulmonary mets, desmoplastic small round cell tumor) undergo reduced-intensity conditioning (fludarabine/melphalan/200 cGy TBI) followed by T cell–replete haploidentical bone marrow transplant. Post-transplant cyclophosphamide is used for GVHD prophylaxis with a shortened tacrolimus course (to day +90) plus mycophenolate, aiming to enhance graft-versus-tumor while monitoring GVHD and non-relapse mortality.
ClinicalTrials.gov ID: NCT01804634
TrialFetch AI summary: Adults with advanced/metastatic solid tumors after ≥1 prior therapy, with dose expansion focused on anti–PD-1/PD-L1–refractory or –progressed sarcoma subtypes (UPS/MFS, angiosarcoma, bone sarcoma) and Merkel cell carcinoma; ECOG 0–1 required. Patients receive weekly intravenous CRD3874-SI, an investigational small‑molecule allosteric STING agonist designed to enhance cGAMP-mediated type I interferon signaling, with 3+3 dose escalation to RP2D followed by expansion.
ClinicalTrials.gov ID: NCT06021626
TrialFetch AI summary: Pediatric and adult patients (≥10 years) with relapsed/refractory osteosarcoma after ≥1 prior systemic therapy, without curative options and with adequate organ function, receive oral losartan (AT1R blocker aimed at modulating tumor stroma/immune chemokines) plus sunitinib (multikinase VEGFR/PDGFR/c-KIT inhibitor) on a 4-weeks-on/2-weeks-off schedule. Key exclusions include surface/periosteal osteosarcoma, active CNS metastases, significant cardiac disease/QTc prolongation, uncontrolled hypertension, recent major surgery, and use of strong CYP3A4 modulators or QT‑prolonging drugs.
ClinicalTrials.gov ID: NCT03900793
TrialFetch AI summary: Children and young adults (3–39 years) with relapsed/refractory rhabdomyosarcoma after ≥2 prior regimens receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of autologous FGFR4-directed CAR T cells (3A11; second-generation CAR targeting the FGFR4 receptor tyrosine kinase, with truncated EGFR tag for tracking/depletion). Prior stable CNS disease allowed; trial assesses safety, feasibility, and preliminary activity across dose levels (1×10^5–1×10^7 CAR T cells/kg).
ClinicalTrials.gov ID: NCT06865664
TrialFetch AI summary: Adults with unresectable or metastatic sarcoma (including desmoid tumor and chordoma) with measurable disease and at least one injectable lesion receive intratumoral talimogene laherparepvec (oncolytic HSV‑1 expressing GM‑CSF) plus nivolumab (PD‑1 inhibitor) and trabectedin (DNA minor-groove binder) as first–third line therapy. Open-label single-arm regimen treats up to 1 year; excludes active significant immunosuppression/autoimmunity, active CNS mets needing high-dose steroids, HSV-1 complications, and need for systemic antivirals.
ClinicalTrials.gov ID: NCT03886311
TrialFetch AI summary: Children and adolescents with refractory, progressive, or relapsed non-CNS solid tumors (Phase 1; 1–18 years) receive PEEL-224, a PEGylated topoisomerase I inhibitor prodrug delivering SN22, either alone or with vincristine and temozolomide; Phase 2 enrolls neuroblastoma (1–30 years) and rhabdomyosarcoma (1–18 years) cohorts at the RP2D for the combination. CNS primaries/metastases are excluded; prior irinotecan/temozolomide permitted.
ClinicalTrials.gov ID: NCT06721689
TrialFetch AI summary: Adults with HLA-A2–positive advanced solid tumors (synovial sarcoma, myxoid/round cell liposarcoma, NSCLC adenocarcinoma/squamous, or urothelial carcinoma) after appropriate prior therapy receive subcutaneous DS-2243a, a bispecific T‑cell engager targeting CD3 and the HLA‑A*02/NY‑ESO‑1 peptide complex, with step-up dosing. Includes dose escalation and tumor-specific expansion; excludes prior NY‑ESO‑1–targeted therapy and requires measurable disease and ECOG 0–1.
ClinicalTrials.gov ID: NCT06644755
TrialFetch AI summary: Adults with relapsed/refractory B‑cell non‑Hodgkin lymphoma after ≥2 prior regimens (ECOG 0–1) receive LTZ‑301 monotherapy, an investigational bispecific myeloid‑cell engager antibody targeting CD79b to recruit monocytes/macrophages and induce phagocytosis for B‑cell depletion. Excludes CLL/Richter, prior allo/solid organ transplant, recent ASCT/CAR‑T, active CNS disease, HIV, active autoimmune disease, and significant cardiovascular events.
ClinicalTrials.gov ID: NCT07121946
TrialFetch AI summary: Pediatric patients with relapsed/refractory hematologic malignancies (AML with <20% blasts, high-risk ALL, HL/NHL, MDS/MPN) or selected high-risk solid tumors (neuroblastoma, Ewing/PNET, rhabdomyosarcoma, osteosarcoma) lacking a timely matched donor undergo TCR-αβ+ and CD19+ depleted KIR/KIR-ligand–mismatched haploidentical PBSC transplant after risk-adapted conditioning. Post-transplant zoledronate (nitrogen-containing bisphosphonate; farnesyl pyrophosphate synthase inhibitor) is given to activate γδ T cells and potentially enhance antitumor immunity while monitoring GVHD, engraftment, and immune reconstitution.
ClinicalTrials.gov ID: NCT02508038